Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial
Vertex Partners With World Champion Skier Lindsey Vonn to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe Acute Pain
Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team
AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions
A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up
A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up
Vertex Signs Letter of Intent with the pan-Canadian Pharmaceutical Alliance for ALYFTREK for the Treatment of Cystic Fibrosis
Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia
Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5-11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions
Copper Intelligence and CoTec Finalise Joint Venture Shareholder Agreement to Target Processing Historical Copper Tailings Opportunities in the Democratic Republic of Congo
Edgewater Wireless Reports First Quarter Fiscal 2027 Results and Advances PrismIQ Commercialization Roadmap
